What You'll Want to Know About Sarepta Therapeutics' Q2 Results
Sarepta Therapeutics (NASDAQ: SRPT) has taken investors on a roller-coaster ride so far in 2019. The stock has swung up and down multiple times -- and not always because of something the biotech itself did. For example, in June, Sarepta's share price soared due to Pfizer announcing disappointing results for its experimental Duchenne muscular dystrophy (DMD) drug.
Sarepta reported its second-quarter results after the market closed on Wednesday. Investors didn't seem very happy with those results, though, with shares falling over 2% in after-hours trading. Here are the highlights from the company's Q2 update.
Image Source: Getty Images.
Quelle Fool.com
